Head & Neck/Thyroid Cancers
From the Journals
Negative results when immunotherapy was added to chemoradiotherapy
A phase 3 trial investigating the addition of avelumab to chemoradiotherapy in patients with head and neck cancer was stopped early.
Clinical Insights
Steroid-refractory pneumonitis from ICIs: Experience at major centers
Conference Coverage
In low-risk thyroid cancer, no advantage found for postsurgical iodine
Forgoing postoperative radioactive iodine in low-risk differentiated thyroid cancer is supported by phase 3 data.
From the Journals
Financial toxicity linked to survival time in head and neck cancer
From the Journals
Increase in thyroid cancer rates points to overscreening
Large but variable increases in rates of papillary thyroid cancer may point to the “diagnostic pressure” of opportunistic high-sensitivity...
From the Journals
Don’t delay: Cancer patients need both doses of COVID vaccine
For patients with cancer, immune response to the first dose of the Pfizer COVID-19 vaccine is reduced, and there is a need for a booster dose at...
Clinical Insights
mCODE: Improving data sharing to enhance cancer care
Guidelines
ASCO, CSCO outline ‘best practices’ for nasopharyngeal carcinoma
Experts mined studies in nasopharyngeal carcinoma to create new guidelines.
Clinical Insights
How has the pandemic affected rural and urban cancer patients?
Conference Coverage
CXR-Net: An AI-based diagnostic tool for COVID-19
The tool showed promise in a pilot study.
From the Journals
Cisplatin tops cetuximab for advanced head and neck cancer